Photo of David A. Reardon,  MD

David A. Reardon, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2166
Fax: (617) 632-4773

David A. Reardon, MD

Dana-Farber Cancer Institute


  • Associate Professor, Medicine, Harvard Medical School
  • Clinical Director, Center for Neuro-Oncology, Medical Oncology, Dana-Farber Cancer Institute


Research Abstract

My career objective has been to improve outcome for brain tumor patients. Initially (July 1995-Dec 1998), I ran a laboratory at St. Jude Children’s Research Hospital dedicated to identifying genetic abnormalities in pediatric brain tumors and conducted clinical research. Thereafter I joined the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke University (Oct 2000-July 2011) as an adult neuro-oncologist where I led daily clinical/translational research operations as Associate Deputy Director. We saw 800 brain tumor referrals and conducted 10-15 clinical trials annually. I also led the in vivo preclinical testing program which included 100 established CNS tumor cell lines and 50-60 patient-derived primary tumor xenografts. Each year we evaluated 50-75 investigational compounds for anti-tumor activity in flank and orthotopic, intracranial human brain tumor models. Via this effort, we successfully transitioned several preclinical compounds into clinical trials for brain tumor patients. I co-authored over 100 peer-reviewed manuscripts, was awarded an R21 NIH grant, and served as principal investigator of clinical core sections of an awarded brain SPORE grant and two program project grants. I also conducted several noteworthy, multi-center phase I-II clinical trials for neuro-oncology patients, two of which led to pivotal phase III studies evaluating cilengitide, as well as imatinib plus hydroxyurea, respectively, for glioblastoma. I also taught 1-3 neuro-oncology fellows per year who were supported through a NCI T-32 award. My clinical and research efforts at Duke were recognized by receipt of the R. K Rundles Award for Excellence in Clinical Oncology Research in 2007.

I came to the Center for Neuro-Oncology at DFCI (July 2011) because the research opportunity offered unmatched potential for neuro-oncology. I joined an outstanding team led by long-term friend and collaborator, Patrick Wen that has fostered several exciting endeavors. First, I am leading preclinical studies evaluating immune based therapies using an orthotopic, immunocompetent glioblastoma model, in collaboration with outstanding colleagues from the DFCI cancer immunology group including Gordon Freeman and Glenn Dranoff. Results of this work have supported development of several clinical trials which are anticipated to initiate soon. In addition, this work led to the award of a $1.5 million dollar grant ($500,000 per year for 3 years) from the Ben and Catherine Ivy Foundation to expand preclinical and clinical efforts. I have also been awarded funding from pharmaceutical companies for preclinical studies evaluating pipeline agents in glioblastoma animal models. Second, I have helped significantly expand the clinical research portfolio of our Center. I currently serve as principal investigator for 6 clinical trials that I opened in the past year. My additional accomplishments since coming to DFCI include: 1) publishing 50 peer-reviewed manuscripts; 2) conducting a neuro-oncology CME program for community neuro-oncologists that has become an annual endeavor; 3) leading separate institutional workshops on cutting edge therapies for meningioma patients and immunotherapy for glioblastoma; 4) providing 57 presentations (18 local, 18 national and 21 international); and and training 1-2 neuro-oncology fellows annually. Finally, in November 2013, I was elected President of the Society for Neuro-Oncology, the major society in the field.



Powered by Harvard Catalyst
  • Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam do H, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. 2015; 17:708-17. PubMed
  • Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. 2015; 17:764-5. PubMed
  • Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. 2015; 17:488-504. PubMed
  • Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol 2015; 17:343. PubMed
  • Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. Int J Radiat Oncol Biol Phys 2015. PubMed
  • Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9. PubMed
  • Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, Agar NY, Rodig SJ, Bradshaw EM, Santagata S. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. 2015; 6:4704-16. PubMed
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J. Neurooncol. 2015. PubMed
  • Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 2015; 12:69-70. PubMed
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280-6. PubMed
  • Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 2015. PubMed
  • Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. 2015. PubMed
  • Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, Al-Mefty O, Wen PY, Reardon DA, Lee EQ, Nayak L, Rinne ML, Beroukhim R, Weiss SE, Ramkissoon SH, Abedalthagafi M, Santagata S, Dunn IF, Alexander BM. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. 2014. PubMed
  • Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J. Neurooncol. 2014. PubMed
  • Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. 2014.